Mucopolisacaridosis tipo VI: Reporte de tres casos y revisión de la literatura

Melean Gumiel, Germán; Ayllón López, Valeria; Taboada Lopez, Gonzalo.
Rev. méd. (La Paz) ; 25(2): 58-64, Jul. Dic., 2019.
Artículo en Español | LILACS | ID: biblio-1102699

Documentos relacionados

  1. Compound heterozygous missense mutations in a Chinese mucopolysaccharidosis type VI patient: a case report.
  2. Phenotypic expansion of ARSK-related mucopolysaccharidosis.
  3. Profound Impact of Decline in N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on Molecular Pathophysiology and Human Diseases.
  4. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
  5. Neutrophils and monocytes with increased azurophilic granules resembling toxic changes in mucopolysaccharidosis type VI.
  6. Mucopolysaccharidosis Type VI, an Updated Overview of the Disease.
  7. Oral treatment for mucopolysaccharidosis VI: Outcomes of the first phase IIa study with odiparcil.
  8. MPS VI associated ocular phenotypes in an MPS VI murine model and the therapeutic effects of odiparcil treatment.
  9. Tandem mass spectrometric assay of N-acetylglucosamine-6-sulfatase for multiplex analysis of mucopolysaccharidosis-IIID in dried blood spots.
  10. Clinical, Endocrine and Genetic spectrums of Mucopolysaccharidoses type VI in Duhok city, Kurdistan Region, Iraq.